{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:20:04Z","timestamp":1767676804949,"version":"build-2065373602"},"reference-count":10,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T00:00:00Z","timestamp":1635033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Despite improvements in the diagnosis and treatment of cancers, the incidence of pituitary metastasis has increased. Prostate cancer metastasis to the pituitary, however, is rare, and these tumors usually grow rapidly. They are also more likely to be located in the posterior pituitary, and the presenting symptoms are often nonspecific, which makes early diagnosis challenging. The management of this condition is usually multidisciplinary, and requires careful assessment and decision making. We present a case of a patient who developed prostate cancer metastasis to the pituitary. In this report, we show that patients with prostate cancer on corticosteroid therapy who develop withdrawal symptoms or other endocrine symptoms should be assessed for pituitary and other brain metastasis. This case report also discusses the impact of switching from prednisone and abiraterone to dexamethasone and abiraterone. Our report shows that patients on abiraterone and prednisone whose PSA has increased, but who have no radiologic progression, may have their PSA controlled and thereby improved survival time when they are switched to abiraterone and dexamethasone.<\/jats:p>","DOI":"10.3390\/curroncol28060365","type":"journal-article","created":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T22:06:16Z","timestamp":1635113176000},"page":"4291-4297","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prostate Cancer Metastasis to the Pituitary Gland Manifesting as Corticosteroid Withdrawal, and the Impact of the Switch from Prednisone to Dexamethasone on Survival Time"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4389-6738","authenticated-orcid":false,"given":"Okeroghene","family":"Ataikiru","sequence":"first","affiliation":[{"name":"Oncology Clinical Trials, Horizon Health Network\u2014The Moncton Hospital, Moncton, NB E1C 6Z8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Abdelsalam","sequence":"additional","affiliation":[{"name":"Oncology and Hematology Division, Horizon Health Network\u2014The Moncton Hospital, Moncton, NB E1C 6Z8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrudula","family":"Avileli","sequence":"additional","affiliation":[{"name":"Oncology Clinical Trials, Horizon Health Network\u2014The Moncton Hospital, Moncton, NB E1C 6Z8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trina","family":"Hynes","sequence":"additional","affiliation":[{"name":"Oncology Clinical Trials, Horizon Health Network\u2014The Moncton Hospital, Moncton, NB E1C 6Z8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1530\/EC-18-0338","article-title":"Pituitary metastasis: A rare condition","volume":"7","author":"Javanbakht","year":"2018","journal-title":"Endocr. Connect"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11060-020-03396-w","article-title":"Current status and treatment modalities in metastases to the pituitary: A systematic review","volume":"146","author":"Ng","year":"2020","journal-title":"J. Neurooncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41416-018-0123-9","article-title":"Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)","volume":"119","author":"Lozano","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0090-4295(03)00367-4","article-title":"Rare case of metastatic prostate adenocarcinoma to the pituitary","volume":"62","author":"Patel","year":"2003","journal-title":"Urology"},{"key":"ref_5","first-page":"243","article-title":"Initial symptomatic pituitary metastasis in a patient with prostate foamy gland carcinoma: Tailoring safe and effective therapy","volume":"54","author":"Zadravec","year":"2015","journal-title":"Acta Clin. Croat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coemr.2018.05.001","article-title":"Pituitary and other sellar region metastases","volume":"1","author":"Dias","year":"2018","journal-title":"Curr. Opin. Endocr. Metab. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Y\u0131lmaz, H., Kaya, M., Can, M., Ozbek, M., and Keyik, B. (2012). Metastatic prostate adenocarcinoma presenting central diabetes insipidus. Case Rep. Med., 2012.","DOI":"10.1155\/2012\/452149"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1210\/jc.2003-030395","article-title":"Tumors metastatic to the pituitary gland: Case report and literature review","volume":"89","author":"Komninos","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11102-020-01034-2","article-title":"Pituitary metastases: Presentation and outcomes from a pituitary center over the last decade","volume":"23","author":"Lithgow","year":"2020","journal-title":"Pituitary"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1677\/joe.0.1690263","article-title":"Anterior pituitary trophic responses to dexamethasone withdrawal and repeated dexamethasone exposures","volume":"169","author":"Nolan","year":"2001","journal-title":"J. Endocrinol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/6\/365\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:22:28Z","timestamp":1760167348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/6\/365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,24]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["curroncol28060365"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28060365","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2021,10,24]]}}}